Citigroup Inc Prometheus Biosciences, Inc. Transaction History

Citigroup Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$103.46 - $126.29 $5.39 Million - $6.58 Million	52,077 Added 154.62%	85,757 $9.2 Million
Q4 2022 Feb 09, 2023	SELL	$36.06 - $117.21 $1.94 Million - $6.29 Million	-53,685 Reduced 61.45%	33,680 $3.7 Million
Q3 2022 Nov 10, 2022	BUY	$28.17 - $59.01 $2.38 Million - $4.99 Million	84,584 Added 3041.5%	87,365 $5.16 Million
Q2 2022 Aug 10, 2022	SELL	$22.39 - $38.94 $145,557 - $253,148	-6,501 Reduced 70.04%	2,781 $78,000
Q1 2022 May 12, 2022	BUY	$30.13 - $50.0 $8,587 - $14,250	285 Added 3.17%	9,282 $350,000
Q4 2021 Feb 10, 2022	BUY	$22.28 - $39.54 $171,711 - $304,734	7,707 Added 597.44%	8,997 $356,000
Q3 2021 Nov 10, 2021	BUY	$20.89 - $26.96 $26,948 - $34,778	1,290 New	1,290 $31,000

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.